Table 2.
Hematological and organ response for patients with AL amyloidosis treated with CyBorD and CyBorMe at the Tom Baker cancer center
| Characteristic | CyBorD group | CyBorMe group | P value |
|---|---|---|---|
| Overall response rate (ORR) | 90.6% | 92.8% | 0.9 |
| Complete response (CR) | 28.5% | 35.7% | |
| Very good partial response (VGPR) | 33.3% | 35.7% | |
| Partial response (PR) | 30.9% | 21.4% | |
| **MRD neg CR by flow cytometry | 10.2% | 28.5% | 0.2 |
| Time to first response (weeks, median) | 6 | 4 | 0.002 |
| dFLC at 1 month (median) | 31 | 25 | 0.3 |
| Time to best response (weeks) | 12 weeks | 4 weeks | 0.007 |
| Median number of cycles | 4 | 3 | 0.8 |
| Discontinuation | 25% | 7% | 0.1 |
| Organ response | 34% | 35.7% | 0.9 |
| Cardiac response | 31% (9/29) | 44% (4/9) | 0.4 |
**Minimal Residual Disease (MRD) assessment by flow cytometry